CHIH-YUAN WANGKUO-CHIN HUANGCHIA-WEN LUChu, Chih-HsunChih-HsunChuHuang, Chien-NingChien-NingHuangChen, Harn-ShenHarn-ShenChenLee, I-TeI-TeLeeChen, Jung-FuJung-FuChenChen, Ching-ChuChing-ChuChenChen, Chung-SenChung-SenChenHsieh, Chang-HsunChang-HsunHsiehTien, Kai-JenKai-JenTienChien, Hung-YuHung-YuChienHuang, Yu-YaoYu-YaoHuangHsu, Jui-PaoJui-PaoHsuShane, Guang-TzuuGuang-TzuuShaneChang, Ai-ChingAi-ChingChangWu, Yen-ChiehYen-ChiehWuSheu, Wayne Huey-HerngWayne Huey-HerngSheu2022-12-192022-12-192022-09-280021-972Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/626604There is a medical need for effective insulin-independent antidiabetic drugs that can promote pancreatic β-cell function and have a low risk of hypoglycemia in type 2 diabetes mellitus (T2DM) patients. R-form verapamil (R-Vera), which is able to enhance the survival of β-cells and has higher cardiovascular safety margin compared with racemic verapamil, was developed as a novel approach for T2DM treatment.enHbA1c; R-form verapamil; antidiabetic drug; metformin; type 2 diabetes[SDGs]SDG3journal article10.1210/clinem/dgac436359175802-s2.0-85139375445WOS:000837742300001https://api.elsevier.com/content/abstract/scopus_id/85139375445